We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $476M
1-Year Est. Return 128.63%
This Fund
S&P 500
This Quarter Est. Return
-11.33%
1 Year Est. Return
+128.63%
3 Year Est. Return
+700.94%
5 Year Est. Return
+846.44%
10 Year Est. Return
–
AUM
$192M
AUM Growth
-$42.3M
Cap. Flow
-$8.2M
Cap. Flow %
-4.28%
Top 10 Hldgs %
97.01%
Holding
14
New
–
Increased
3
Reduced
–
Closed
1

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$2.06M
2
TECX
Tectonic Therapeutic
TECX
+$1.53M
3
NBRV
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
+$228K

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BBIO icon
1
BridgeBio Pharma
BBIO
$15.7B
$82.4M 42.93%
3,835,722
– –
EIDX
2
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$40.4M 21.07%
1,123,630
– –
TECX
3
Tectonic Therapeutic
TECX
$529M
$12.6M 6.57%
74,423
+6,756
+10% +$1.53M
OBSV
4
DELISTED
ObsEva SA Ordinary Shares
OBSV
$11.5M 6.02%
1,386,338
– –
MRKR icon
5
Marker Therapeutics
MRKR
$18.8M
$10.2M 5.33%
200,000
– –
SYRE icon
6
Spyre Therapeutics
SYRE
$8.54B
$9.93M 5.18%
51,646
– –
VIRX
7
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$7.27M 3.79%
288,571
+71,428
+33% +$2.06M
BCEL
8
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$4.75M 2.47%
387,653
– –
NBRV
9
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.82M 1.99%
7,641
+404
+6% +$228K
ZSAN
10
DELISTED
Zosano Pharma Corporation
ZSAN
$3.17M 1.65%
57,959
– –
RCUS icon
11
Arcus Biosciences
RCUS
$3.55B
$3.03M 1.58%
333,333
– –
VRNA
12
DELISTED
Verona Pharma
VRNA
$2.03M 1.06%
443,596
– –
ACRS icon
13
Aclaris Therapeutics
ACRS
$726M
$685K 0.36%
634,455
– –
BHVN
14
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-274,513
Closed -$12M

Similar funds

BF
Brooklyn FI New York $476M AUM 17.97% 1-Year Est. Return
VIA
Vickerman Investment Advisors Spokane, Washington $476M AUM 12.21% 1-Year Est. Return
DE
Devon Energy Houston, Texas $476M AUM
FAM
Frontier Asset Management Sheridan, Wyoming $477M AUM 19.41% 1-Year Est. Return
BHWA
Beacon Harbor Wealth Advisors Virginia Beach, Virginia $477M AUM 49.25% 1-Year Est. Return
AL4A
Accel Leaders 4 Associates Palo Alto, California $475M AUM 391.52% 1-Year Est. Return
LEFP
Leading Edge Financial Planning Knoxville, Tennessee $475M AUM 15.22% 1-Year Est. Return
MVP
Medina Value Partners Los Angeles, California $477M AUM 25.52% 1-Year Est. Return

Aisling Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Aisling Capital Management held 14 positions worth $192M, down 18% from $234M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Aisling Capital Management withdrew a net $8.2M in Q3 2019, closing 1 position. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $12M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Aisling Capital Management added an estimated $2.06M to Viracta Therapeutics, Inc. Common Stock.

  • Aisling Capital Management added most to Viracta Therapeutics, Inc. Common Stock in Q3 2019, an estimated $2.06M increase.
  • Aisling Capital Management fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019, selling an estimated $12M.
  • Aisling Capital Management's ten largest holdings make up 97% of its $192M portfolio in Q3 2019.
  • Aisling Capital Management opened 0 new positions and closed 1 in Q3 2019.
  • Aisling Capital Management's portfolio value fell 18% quarter-over-quarter to $192M.

Based on Aisling Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.